Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck by Pivot, X et al.
Squamous cell carcinoma of the head and neck (SCCHN) is the
sixth most common form of cancer worldwide, with more than 
500 000 new cases occurring in 1999 (Landis et al, 1999). In the
United Kingdom, 6650 new cases and 2000 deaths from this
disease were reported in 1997 (World Health Organization, 2000).
Patients who present with an early stage of SCCHN can be
successfully treated with a combination of surgery and/or radia-
tion. However, up to 75% of SCCHN patients develop advanced
locoregional disease (T2–T4, N2–N3) (Vokes et al, 1993). For
these patients, the clinical outcome with traditional surgery and/or
radiation is much less satisfactory. Newer therapies have led to
alternative treatment regimens for these patients. Induction
chemotherapy has led to organ preservation via a reduction of
surgical indication, and chemoradiotherapy has improved survival
in patients with inoperable disease (Dimery et al, 1993). Patients
with advanced disease at diagnosis have a 5-year survival rate of
only 30% and approximately 6 in 10 patients will experience a
locoregional relapse within 2 years of initial treatment. The prog-
nosis for patients with locally recurrent or metastatic disease is
dismal, with a median survival time of approximately 6 months
(Pivot et al, 2000). However, salvage options, such as additional
surgery or radiation therapy, are limited in these cases. Recurrent
locoregional disease is generally incurable, as is metastatic disease
that occurs in approximately 20% of patients. For these patients,
chemotherapy has become commonly accepted as standard
therapy and used primarily as a palliative treatment. 
Methotrexate monotherapy is considered to be a standard
therapy for recurrent head and neck cancer. Tumour response 
rates to single-agent methotrexate therapy range from 10% to
17%, with a median response duration of approximately 3 months
(Schornagel et al, 1995). Survival for this patient population has
not changed appreciably in the past 2 decades. While combination
drug regimens have produced encouraging response rates, signifi-
cantly higher than those observed with single-agent methotrexate
alone, no significant survival advantage has been demonstrated
(Vogl et al, 1985; Anon, 1990; Forastiere et al, 1992). Investigation
of new therapies is needed in order to improve overall survival for
these patients. 
Pemetrexed disodium is a structurally modified folate analogue
that suppresses both DNA synthesis and folate metabolism.
Specifically, pemetrexed potently inhibits thymidylate synthase
(TS) and dihydrofolate reductase (DHFR). This antimetabolite has
also been found to inhibit glycinamide ribonucleotide formyl
transferase (GARFT) and aminoimidazole carboxamide ribonu-
cleotide formyltransferase (Shih et al, 1997; Chen et al, 1999).
Pemetrexed is a classic antifolate that is converted intracellularly
to polyglutamated derivatives by folypolyglutamate synthase.
These polyglutamated forms have shown much greater inhibitory
activity against TS and GARFT than its parent compound,
although the inhibition of DHFR was unaffected by polyglutama-
tion (Mendelsohn et al, 1999). 
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pemetrexed disodium, a new multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase and glycinamide
ribonucleotide formyl transferase. 35 patients with local or metastatic relapse of squamous cell carcinoma of the head and neck (31 male, 4
female; median age 53 years) were treated with pemetrexed 500 mg m2 administered as a 10-minute infusion on day 1 of a 21-day cycle.
Patients received 1 to 8 cycles of therapy. 9 patients (26.5%) had an objective response, with a median response duration of 5.6 months
(range 2.9–20 months). 15 (44.1%) had stable disease, and 8 (23.5%) had progressive disease. 2 patients were not assessable for response.
Median overall survival was 6.4 months (range 0.7–28.1 months; 95% CI: 3.9–7.7 months). 24 patients (68.6%) experienced grade 3/4
neutropenia, with febrile neutropenia in 4 (11.4%). Grade 3/4 anaemia and thrombocytopenia occurred in 11 (34.3%) and 6 (17.1%) patients,
respectively. The most frequent non-haematological toxicity was grade 3/4 mucositis (17.1%; 6 patients). In conclusion, pemetrexed is active
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range of tumours, including breast, non-small-cell lung, colorectal
and pancreas cancers (O’Dwyer, 1999; Postmus and Green, 1999;
Rusthoven et al, 1999; John et al, 2000). Response rates have
ranged from 31% in breast and 16–23% in non-small-cell lung
cancers to 16% in colorectal and 6% in pancreatic cancers. Phase
II studies thus far have employed a dose schedule of pemetrexed
disodium at either 500 or 600 mg m–2 as a 10-minute i.v. infusion
once every 21 days. As expected from a DNA synthesis inhibitor, the
most serious and common adverse events were haematological toxic-
ities. Because of the broad range of activity of pemetrexed disodium
in various cancers, the present study was undertaken to investigate
the safety and efficacy of this agent in patients with locally advanced
or metastatic head and neck cancers. Additionally, the study assessed
the pharmacodynamics and pharmacokinetics of pemetrexed
disodium in this patient population.
MATERIALS AND METHODS 
Patient eligibility 
Patients were eligible for this trial if they had histologically
confirmed squamous cell carcinoma of the head and neck that
recurred locally or as distant metastatic disease. A bidimensionally
measurable lesion with clearly defined margins was required.
Lesions could not be amenable to curative surgery or radiotherapy.
Prior radiotherapy was allowed, but a minimum of 6 months was
required between the completion of prior radiotherapy and entry
into the study and the irradiated area could not be the only site of
measurable disease. Prior chemotherapy was allowed only if used
as an induction strategy or as a concomitant chemoradiotherapy
treatment and must have been completed 6 months prior to study
entry. An estimated life expectancy of at least 12 weeks and an
Eastern Cooperative Oncology Group performance status of 0 to 2
were required for study entry. Adequate organ function as defined
by the following was required: platelets ≥ 100 × 109 l–1, haemo-
globin ≥ 9gd l –1, absolute granulocyte count (AGC) ≥ 2.0 × 109 l–1,
bilirubin ≤ 1.5 times the upper limit of normal, aspartate transami-
nase (AST) or alanine transaminase (ALT) ≤ 3.0 times normal
(AST or ALT ≤ 5 times normal was acceptable if due to liver
disease), and calculated creatinine clearance ≥ 45 ml min–1.
Patients had to give informed consent. 
Patients were excluded from the study if they had a second
primary malignancy, except for an in situ carcinoma of the cervix
or adequately treated basal cell carcinoma of the skin or other
malignancy treated at least 5 years previously with no evidence of
recurrence. Patients with clinically significant effusions (pleural or
peritoneal) or albumin < 2.5 gm dl–1 were ineligible for the study.
Additionally, patients could not have undifferentiated and non-
keratinizing carcinomas. Patients with active infection or sympto-
matic brain metastasis or who were pregnant were excluded from
the study. The use of any investigational agent 30 days before enroll-
ment in the study was forbidden. Patients who could not discontinue
therapy with aspirin and other non-steroidal anti-inflammatory
agents for 2 days before, the day of, and 2 days after administration
of pemetrexed disodium were excluded from the trial. 
Study design 
This phase II multicentre study was designed as a single-arm,
open-label, two-stage, (Fleming et al, 1997) nonrandomized trial.
Pemetrexed was administered at a dose of 500 mg m–2as a 10-minute
i.v. infusion once every 21 days. Dexamethasone 4 mg, a prophy-
lactic measure for skin rash, was taken orally twice a day starting
the day before and continuing until the day after pemetrexed
administration (Calvert and Walling, 1998). Dose adjustments
were based on nadir counts and/or maximal non-haematological
toxicity from the preceding cycle of therapy. Specifically, grade 3
and grade 4 mucositis required a 25% and a 50% dose reductions,
respectively. Grade 4 neutropenia lasting more than 5 days
required a 15% dose reduction. Grade 3 and grade 4 thrombocy-
topenia required 15% and 50% dose reductions, respectively.
A 25% dose reduction was required in case of concomitant
grade 4 neutropenia and grade 3 thrombocytopenia. Neutrophil
count was required to be >1.5 × 109 l–1 and platelets
> 100 × 109 l–1 prior to the start of any cycle. Otherwise, treatment
was delayed up to 2 weeks to allow sufficient time for recovery.
If, after the 2-week delay, neutrophil and/or platelet counts had
not surpassed these levels, then the patient was removed from the
study. If a patient had a calculated creatinine clearance < 45 ml
min–1, then the next cycle would not begin until the calculated
creatinine clearance value was ≥ 45 ml min–1. If a patient’s calcu-
lated creatinine clearance had not returned to ≥ 45 ml min–1
within 6 weeks, then the patient was removed from the study. No
other chemotherapy, immunotherapy, hormonal cancer therapy
(excluding contraceptives and corticosteroids), radiation therapy
or experimental medications were allowed. Use of granulocyte
colony stimulating factors was not allowed.
Response assessment 
Tumour measurements were assessed by radiological imaging
within 4 weeks prior to study entry and every 6 weeks thereafter.
Specifically, evaluation of efficacy was performed during the third
week following the administration of cycles 2, 4 and 6. All
responses were reviewed by a panel of independent investigators
and were determined using SWOG criteria. A complete response
(CR) was defined as the disappearance of all measurable and
evaluable disease, with no new lesion. Partial response (PR) was
applied to patients who had a decrease in the sum of products of all
measurable lesions greater than or equal to 50%, with no progres-
sion of evaluable disease and no new lesions. Progressive disease
(PD) was defined as a 25% increase in the sum of products of all
measurable lesions, the reappearance of any lesion which had
disappeared, or the appearance of any new lesion. Stable disease
(SD) was defined as any response which did not qualify as a CR,
PR or PD. All responding patients were required to have a 4-week
confirmation imaging. The duration of response was defined as the
time from first objective status assessment of CR or PR to the first
sign of disease progression or death due to any cause. Time-to-
treatment failure (TTF) was defined as the time from study entry to
the first observation of disease progression or death due to any
cause or early discontinuation of treatment. Overall survival (OS)
was defined as the time from study entry to time of death due to
any cause. 
Pharmacokinetic analysis 
Blood samples were collected for analysis of pemetrexed in
plasma during cycles 1 and 3. The samples were collected
according to a randomization schedule during each of 4 collection
intervals: 0 to 2, 2 to 6, 6 to 12 and 12 to 36 hours after the start of
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selected based on the full pharmacokinetic profile obtained from a
phase I study (Rinaldi et al, 1999) and will provide an adequate
characterization of the pharmacokinetic profile after intravenous
administration. 
The pharmacokinetics of pemetrexed in patients with head and
neck cancer were evaluated as part of a population pharmacokinetic
model developed from plasma pemetrexed concentration–time data
collected in patients with colorectal, pancreatic, breast, oesophageal,
renal, head and neck, bladder or cervical cancers. Plasma concentra-
tion–time data from 8 studies, each evaluating a single cancer type,
were combined into a single data set and analysed. An open 2-
compartment model parameterized in terms of clearances and
volumes was used for the structural model. 
Pharmacokinetic analysis was performed using population
pharmacokinetic methods (Mandema et al, 1992) with the non-
linear mixed-effects modelling program, NONMEM (Version 5,
PREDPP 5). A final population pharmacokinetic model including
statistically significant covariates was developed using a data set
containing 1184 concentrations from 209 patients; of these, 162
concentrations were from 26 patients with SCCHN (analyses on
file). Plasma clearance (CL) was dependent on creatinine clear-
ance. Central volume of distribution (V1) was a function of body
surface area. Peripheral volume (V2) and intercompartmental
clearance (Q) were independent of the covariates examined. 
The effect of the study population (i.e. cancer type) was evalu-
ated by comparing typical CL values between the patients with
SCCHN and those patients without SCCHN using the final popu-
lation pharmacokinetic model and adding an additional parameter
to the final model (Eq. 1) as follows: 
where CLSCCHN is the plasma clearance in patients with head and
neck cancer, CL is the plasma clearance from the population of
patients that did not have head and neck cancer (Eq. 1.), Θ SCCHN
adjusts the plasma clearance in patients with SCCHN, and IND is
a dichotomous indicator variable that distinguishes between the 2
populations. The numerical value of IND was 1 for patients with
SCCHN and 0 for patients with the other cancer types. 
Statistical inference concerning differences in CL between the 2
populations was based upon a comparison of minimum values of
the NONMEM objective functions (MOF) between the final 
population model and the model incorporating an effect for study
population on CL (Eq. 1). A decrease in the MOF of at least 3.841
(P value ≤ 0.05; 1 degree of freedom) between the 2 models for CL
is required for statistical significance. 
Statistical analysis 
All estimated confidence interval parameters were designed with a
significance level of α = 0.05. The efficacy analysis was performed
on data from all protocol-qualified patients. The safety analysis
was performed on data from all patients who received at least one
dose of the study drug. Time-to-event endpoints of overall survival
(OS), time-to-failure (TTF), and response duration were evaluated
with Kaplan–Meier non-parametric methods using JMP®
Software (SAS, Cary NC). The pharmacodynamic and pharmaco-
kinetic comparisons of the pemetrexed disodium blood concentra-
tion between patients from this study and other phase II studies
were performed using a Spearman rank test. 
RESULTS 
Patient characteristics 
Between May 1997 and February 1999, 35 patients (31 males, 4
females) were enrolled in the study. All patients were assessable
for safety and 34 patients were assessable for response. The
median age was 53 years (range 38–75 years). Median ECOG
performance status was 1 (range 0–2). Before entering into the
study, all but 2 patients had been previously treated with surgery
and/or radiotherapy. The 2 previously untreated patients had
distant metastases at initial presentation. 14 patients (40%) had
previously received chemotherapy (cisplatin-fluorouracil combi-
nation), either as induction therapy or as concomitant chemoradio-
therapy. The median interval between initial treatment and relapse
was 11 months (range 6–80 months). 31 patients (88.6%) had
metastatic disease. Involved sites included lung (31 patients), liver
(7 patients), mediastinal (2 patients) and bone (1 patient). 4
patients (11.4%) had only locoregional disease, and all recurrences
were outside an area previously treated by radiotherapy. 18
patients (51.4%) had both locoregional recurrence and metastatic
disease. Table 1 summarizes patient characteristics. 
Response and survival results 
Among the 35 enrolled patients, 34 were considered evaluable for
response according to protocol. One patient was not evaluable for
efficacy because he did not have a bidimensionally measurable
lesion outside an area previously untreated by radiotherapy. This
patient achieved a PR in the oral cavity lesion and a CR in the lung
lesion, with a response duration longer than 16 months. 
Confirmed PR was observed in 9 patients, giving a 26.5%
response rate (95% CI: 12.9–44.4%). The median response dura-
tion was 3.9 months (range 2.9–20 months; 95% CI: 2.1–7.2
months). SD was observed in 15 patients (44.1%), and 8 patients
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Table 1 Patient characteristics
Characteristic No. of patients % 
Entered 35 100 
Evaluable 
Safety 35 100 
Efficacy 34 97.1 
Age 
Median 53 years 
Range 38–75 years 
Gender 
Male 31 88.6 
Female 4 11.4 
ECOG performance status 
0 9 25.7 
1 22 62.9 
2 4 11.4 
Prior therapy 
Surgery 23 65.7 
Radiotherapy 27 77.1 
Chemotherapy 14 40.0 
Site of recurrence 
Local recurrence only 4 11.4 
Metastatic 31 88.6 
Metastatic sites 
Lung 31 88.6 
Liver 7 20 
Mediastinum 2 5.7 
Bone 1 2.9 
CL
SCCHN= CL• (1+Θ
SCCHN •IND) (1)
BJOC 01-2010 649-655  20/8/01  3:57 pm  Page 651(23.5%) had a PD as a best response. In addition, 2 of the 34 
efficacy-evaluable patients were not assessed for response. One
patient died after one cycle of therapy due to haemorrhage
possibly related to study drug. The second patient discontinued
after one cycle of therapy due to infection possibly related to study
drug. These results are detailed in Table 2. 
At the time of this report, 5 of the 35 patients enrolled in the
study are alive. Median overall survival for all patients was 7.3
months (range 0.7–28.1 months; 95% CI: 3.9–7.7 months)
compared to 20.4 months (range 7.3–27.4 months; 95% CI:
7.3–28.1 months) for responders. Due to censoring, the upper end
of the 95% confidence interval was nonestimable. The 1-year
survival rate for all patients was estimated to be 29% (Figure 1).
Median time-to-treatment failure was 3.9 months (range 0.7–28.1
months; 95% CI: 2.8–9.0 months) (Figure 2). 
Safety 
24 patients (68.6%) experienced grade 3/4 neutropenia, with
febrile neutropenia occurring in 4 patients (11.4%) (Table 3).
Grade 3/4 anaemia and thrombocytopenia were observed in 12
(34.3%) and 6 (17.1%) patients, respectively. 2 patients died due to
neutropenic sepsis, and 2 patients died due to tumoral bleeding
associated with grade 4 thrombocytopenia. 2 patients discontinued
the study after the first cycle due to pulmonary sepsis. 
The most common grade 3/4 non-haematological toxicity was
mucositis, observed in 6 patients (17.1%) (Table 4). Other severe
non-haematologic toxicities occurred infrequently and included
skin rash (3 patients; 8.6%), nausea (1 patient; 2.9%), vomiting 
(1 patient; 2.9%), and diarrhoea (1 patient; 2.9%). 
A total of 134 cycles of pemetrexed was administered. The
median number of cycles per patient was 4 (range 1–6 cycles).
Grade 3/4 toxicities occurring by percent of cycle included
neutropenia (35.8%), anaemia (10.5%), thrombocytopenia
(5.2%), febrile neutropenia (5.2%), and mucositis (5.2%) (Table
5). The duration of neutropenia was short (median duration 1.9
days, ranged between 1 to 5 days), and there was no evidence of
cumulative toxicity. Importantly, pemetrexed did not exhibit
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Table 2 Response rates 
Enrolled patients (n = 35) Efficacy evaluable patients (n = 34) 
Partial response 9 (25.7%; 95% CI 18.2–33.2%) 9 (26.5%; 95% CI: 12.9–44.4%) 
Stable disease 15 (42.9%; 95% CI 31.6–48.4%) 15 (44.1%; 95% CI: 27.2–62.1%) 
Progressive disease 8 (22.9%; 95% CI 18.2–33.2%) 8 (23.5%; 95% CI: 10.7–41.2%) 
Not done 3 (8.6%) 2 (5.8%) 
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Table 3 Haematological toxicities (n = 35 patients) 
Grade 0–1 Grade 2 Grade 3 Grade 4 
Neutropenia 5 (14.3%) 6 (17.1%) 10 (28.6%) 14 (40.0%) 
Leukopenia 4 (11.4%) 5 (14.3%) 14 (40.0%) 12 (34.3%) 
Anaemia 12 (34.3%) 11 (31.4%) 8 (22.9%) 4 (11.4%) 
Thrombocytopenia 25 (71.5%) 4 (11.4%) 2 (5.7%) 4 (11.4%) 
Febrile neutropenia 4 (11.4%) 
Table 4 Non-haematologic toxicities (n = 35 patients) 
Grade 0–1 Grade 2 Grade 3 Grade 4 
Mucositis 22 (62.9%) 7 (20.0%) 4 (11.4%) 2 (5.7%) 
Skin rash 27 (77.1%) 5 (14.3%) 3 (8.6%) 0 
Nausea 27 (77.1%) 7 (20.0%) 1 (2.9%) 0 
Vomiting 30 (85.7%) 4 (11.4%) 1 (2.9%) 0 
Diarrhoea 31 (88.5%) 3 (8.6%) 1 (2.9%) 0 
Alopecia 35 (100%) 0 0 0 
BJOC 01-2010 649-655  20/8/01  3:57 pm  Page 652significant renal toxicity. Transient deteriorations in liver func-
tion tests were observed, with grade 3 increases in serum levels
of transaminases (15.7%) and bilirubin (4.5%), respectively;
however, no clinical symptoms associated with these changes
were noted. 
86% of the planned dose intensity was delivered. 26% of
patients required a dose reduction and 20% of patients had a 7-day
delayed administration. 
Pharmacokinetic results 
Figure 3 compares plasma pemetrexed concentration as a function
of time for patients with SCCHN to those with other cancer types.
Figure 4 shows the relationship between population predicted and
observed plasma concentrations. Plasma concentrations from
patients with SCCHN overlapped with those from patients with
other cancer types. Therefore, systemic drug exposure in patients
with SCCHN appeared to be consistent with that in patients with
other cancer types. 
The typical value of CL was estimated to be 8% higher (Θ SCCHN =
0.08) in patients with SCCHN than in patients with other cancer
types. This difference was not statistically significant since the MOF
for the model incorporating the effect of study population was less
than 3.841 points lower (P value > 0.05) than the MOF for model
that did not distinguish between SCCHN and other cancer types.
Figure 5 illustrates the distribution of individual Bayesian estimates
of CL between the 2 populations. Therefore, since systemic expo-
sure in patients with SCCHN is consistent with that in patients with
other cancer types, differences in safety results between the popula-
tions are not due to differences in pharmacokinetics. 
DISCUSSION 
The results achieved with pemetrexed disodium in recurrent squa-
mous cell carcinoma of the head and neck are encouraging. The
26.5% PR rate is one of the highest levels of activity for a single
agent reported in this patient population. The 3.8-month response
duration is similar to results obtained with single-agent or combi-
nation chemotherapy regimens for recurrent head and neck cancer
(Jacobs et al, 1983; Vogl et al, 1985; Clavel et al, 1994; Schornagel 
et al, 1995). Likewise, the median overall survival of 6.4 months
achieved in this trial was similar to that reported with other therapies.
Pemetrexed disodium in recurrent head and neck carcinoma 653
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Table 5 Toxicities per cycle (n = 134 cycles) 
Grade 0–1 Grade 2 Grade 3 Grade 4 
Neutropenia 63 (47.0%) 23 (17.1%) 25 (18.7%) 23 (17.2%) 
Leukopenia 46 (34.3%) 39 (29.1%) 35 (26.1%) 14 (10.5%) 
Anaemia 77 (57.5%) 43 (32.1%) 10 (7.5%) 4 (3.0%) 
Thrombocytopenia 116 (86.6%) 11 (8.2%) 3 (2.2%) 4 (3.0%) 
Febrile neutropenia 7 (5.2%) 
Mucositis 120 (89.6%) 7 (5.2%) 6 (4.5%) 1 (0.7%) 
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Figure 3 Comparison of plasma pemmetrexed concentration versus
time data
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chemotherapy administered either as induction treatment or as
concomitant chemoradiotherapy. Interestingly, of the 3 patients
who had failed to respond to cisplatin-fluorouracil induction treat-
ment, 2 patients achieved a PR with pemetrexed. This result
suggests that pemetrexed disodium may be effective in patients
with tumours resistant to cisplatin-fluorouracil therapy. 
Several characteristics of the study population should be consid-
ered when analysing this data. Because eligibility criteria required
the existence of at least one lesion outside an area previously
treated by radiotherapy, the majority of patients (88.6%) in this
study presented with distant metastases. Patients with metastatic
head and neck cancer have poorer outcomes than those with recur-
rent locoregional disease (Pivot et al, 2000). Moreover, data
suggest that chemotherapy may be more effective in locoregional
relapse than in metastatic disease (Recondo et al, 1991). This
difference in terms of activity between metastatic lesion and
locoregional relapse was not consistent in all chemotherapy trials.
A controversial study reported a higher response rate in patients
with metastatic disease than for those with locoregional relapse
(Shin et al, 1998). In a randomized trial, Schornagel et al (1995)
reported that patients with locoregional disease achieved a higher
response rate when compared to patients with metastatic disease
(21% versus 13%, respectively). In the present study that included
patients most likely to be least responsive to chemotherapy, the
26.5% response rate achieved with pemetrexed monotherapy is
promising. 
Although all phase II trials with pemetrexed include pharmaco-
kinetic analysis, the objective of the pharmacokinetic analysis for
this study was to determine if systemic drug exposure in patients
with SCCHN differed from that in patients with other cancer
types. As the trial progressed, it was evident that SCCHN patients
were experiencing haematological toxicities higher than that
previously observed in other pemetrexed trials. Two possible
explanations emerged. First, nutritional status of SCCHN patients,
which is generally poor, played a role in the incidence and severity
of toxicities seen with this antifolate, or second, SCCHN patients
were exposed to higher plasma concentrations of pemetrexed than
patients in earlier studies. In order to investigate these possibilities,
the pharmacokinetics of pemetrexed in SCCHN patients was
compared to that in patients with other cancer types. The typical
value of plasma clearance in patients with SCCHN was shown to
be 8% higher than that from patients with other cancer types.
However, this result was not statistically significant (∆ MOF =
–2.7; P > 0.05). Comparison of plasma concentrations and the
distribution of individual CL values between the 2 populations
showed a large degree of overlap, further illustrating the similari-
ties in pemetrexed pharmacokinetics between the 2 populations.
Since haematological toxicity of pemetrexed has been correlated
with drug exposure, the increase in haematological toxicity in this
study cannot be attributed to drug exposure alone and probably
reflects the generally poor medical condition and advanced disease
state of the patients in this study. 
In support of this conclusion, early preclinical and clinical
studies of antifolates have suggested a link between patient folate
nutritional status and the likelihood of severe toxicity following
treatment with an antifolate (Morgan et al, 1990; Smith et al,
1995; Alati et al, 1996; Mendelsohn et al, 1996). Niyikiza et al
(1998) assessed the relationship between vitamin deficiency markers
(homocysteine, cystathionine and methylmalonic acid), systemic
pemetrexed exposure and patient toxicities. The authors observed
that high homocysteine pretreatment levels, which reflect patient
folate status, were closely related to an increased risk of grade 4
neutropenia and thrombocytopenia, as well as G3/4 diarrhoea
and G3/4 mucositis. Head and neck cancer patients typically
have poor nutritional status and this condition may play a role in
the high incidence of haematological toxicity. Indeed following a
programmatic change to supplement patients with folic acid and
vitamin B12, Bunn et al (2001) reported that haematological and
non-haematological toxicities can be proactively managed. 
In conclusion, pemetrexed has moderate activity in the treat-
ment of patients with recurrent locally advanced or metastatic
squamous cell carcinoma of the head and neck. Further investiga-
tion is warranted to evaluate the therapeutic efficacy of this new
agent in terms of both tumour response and survival either as a
single agent or in combination with other known active agents.
Recently, routine addition of daily low-dose folic acid and vitamin
B12 has been instituted in studies involving pemetrexed disodium.
This supplementation will likely reduce the toxicity in future
studies, especially in nutritionally-challenged patients such as
those studied in this investigation. 
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